Tensions are rising as the government announces the review of the revised supplementary budget bill starting next year amid deepening concerns among pharmaceutical companies over the issue of Choline Alfoscerate. According to the pharmaceutical industry and the medical community on the 1st, it has been confirmed that the MOHW has decided to strengthen the screening of prescriptions for hospitals and clinics starting next year in accordance with the clinical re-evaluation policy for Choline Alfoscerates.

Over the past two years, the MOHW has set the first target of strengthening screening according to the drug clinical re-evaluation policy as the Choline Alfoscerate formulation.

In fact, t